Welcome to Tigermed
Tigermed (Stock code: 300347.SZ/3347.HK) is a leading provider of innovative clinical research solutions across full lifecycle of biopharmaceutical and medical device products globally. With a broad portfolio of services and a promise of quality, from clinical development to commercialization, we are committed to moving our customers and patients through their development journey efficiently and cost-effectively, embracing challenges to fulfill our commitment to serve unmet patients’ needs, and eventually saving lives.
Serve healthcare partners through innovation, advance human health through excellence.
We are committed to improving health by accelerating the development of innovative and effective treatments for patients everywhere. We aim to excel in clinical trials for the benefit of our clients and patients worldwide by providing our services with fundamental principles like quality, innovation, integrity, and ethical conduct at the core of everything we do.
To be recognized as the leading CRO.
We constantly support our clients in advancing human health by delivering science-based value and real outcomes. Our aim is to solidify our market leadership and foster a flourishing ecosystem that contributes to the sustainable and long-term growth of the healthcare industry.
A Company Built on Values
To be consistent and uncompromising in our moral and ethical principles in clinical development.
To promote collaboration among cultures and sharing our knowledge and values with others unconditionally.
To respect authorities, clients, colleagues, and all those we collaborate with to deliver high-quality results that matter.
To provide our clients with any information required science-based decision making, honor our commitments, and take ownership of our work.
Learn More about Our History
Since our inception in 2004, Tigermed has been developing and expanding steadily. We have been adding expertise to our portfolio, experienced colleagues to our teams and subsidiaries to the Tigermed group ever since.
Tigermed was established in Hangzhou on December 15, 2004, and successively set up affiliates in Shanghai, Beijing, Chongqing, and Guangzhou, to complete the framework of functional organization structure.
The Xi’an office opened and the number of employees quickly increased to over 40 colleagues.
The Chengdu and Nanjing offices were set up, and the subsidiary of Shanghai Tigermed Consulting Co., Ltd. was founded.
The Changsha, Shenyang, and Wuhan offices opened.
The Jinan, Tianjin, Harbin, Fuzhou offices opened, and Tigermed had increased the establishment of HunanTiger-Xiangya Drug R&D Co., Ltd.
The offices in Zhengzhou, Changchun, Wenzhou, Kunming, Qingdao were set up in China and the first US-based affiliate opened to enter this market. Meanwhile, Tigermed succeeded in the acquisition of MacroStat (China) Clinical Research Co., Ltd. And during this year, the staff count rose to over 200.
The Nanning and Suzhou offices were set up, Jiaxing Tigermed Data Management Co., Ltd. was established, and the overall number of employees rose to over 400.
This year, 16 offices were set up including offices in Shenzhen, Xiamen, Dalian, Wuxi, Shijiazhuang and the subsidiaries Hangzhou Simo Co., Ltd., Tigermed Research Institute, and Hongkong Tigermed Co., Ltd were set up in the same year.
Tigermed was listed in Shenzhen ChiNex with stock symbol 300347. New offices opened in Hefei, Ningbo, and Taiwan. Additionally, the subsidiaries of Shanghai Tigermed Medical Consulting Co., Ltd. and Fantastic Bio-imaging Co., Ltd. were set up.
The offices in the US, Canada, Australia, Korea, Japan, Malaysia and Singapore were established
Tigermed succeeded in the acquisition of Frontage Laboratories Inc., acquired Beijing Canny Consulting Inc. and Shanghai Suntone International Logistics Co., Ltd. Moreover, the Tigermed Smart Medicine Institute and Jiaxing Clinflash Computer Technology Co., Ltd. were set up.
Tigermed succeeded in the acquisition of South Korea’s largest CRO company DreamCIS Inc. In China, the establishment of Hangzhou Wang Ji Health Technology Co. Ltd., Hangzhou Tai Ji Pharmaceutical Technology Co. Ltd., the acquisition of BMD Co., Ltd.
New offices opened in Zhaoqing, Jiangmen, Huaian, Taizhou, Yancheng, Zhanjiang, and Teddy Clinical Research Laboratory (Shanghai) Co., Ltd. was established.
New offices opened in Binzhou, Liaocheng, and Weihai. Tigermed succeeded in the acquisition of Taizhou Jyton-Kannel Medical Tech.Co. Ltd., and Tigermed Swiss AG. was established.
New offices opened in Jilin, Jiaxing, Taizhou, and Weifang. Tigermed succeeded in the acquisition of Opera Contract Research Organization SRL.
Jointly established Tigerise in Japan with Accerise. Frontage listed on main board of the Stock Exchange of Hong Kong.
A Trusted Partner with Proven Expertise
We are committed to providing our clients with integrated R&D services and solutions in their clinical development in the best possible way.
Every project we conduct and every customer we serve, we do it with excellence. And we are devoted to be excellent in every trial, for every patient.
Since our founding in 2004, we have established a comprehensive suite of biopharmaceutical R&D service offerings, ranging from pre-clinical to commercialization, and primarily focus on clinical stage, including regulatory affairs and submission, clinical operations, data management and statistical analysis, technology platform, medical device, post-marketing and real-world study.
As of Q2 2021, Tigermed is representing a global network of more than 60 subsidiaries and 160 offices and service locations, with over 7,500 employees across 39 countries in Asia Pacific, Europe, North America, South America and Africa.
This set-up enables Tigermed to provide our clients with support in both local expertise in China and global clinical development programs.